Biotinylated Human IL-13 Protein, His,Avitag™

Source : 

Biotinylated Human IL-13, His,Avitag (IL3-H82E5) is expressed from human 293 cells (HEK293). It contains AA Gly 21 - Asn 132 (Accession # AAK53823.1).

 

Molecule : IL-13

 

Synonyms : IL13,ALRH,BHR1,MGC116786,MGC116788,MGC116789,P600,Interleukin-13

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : NP_002179.2

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 15.9 kDa

 

Characteristics :

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag. The protein has a calculated MW of 15.9 kDa. The protein migrates as 17 kDa and 28-37 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : PBS, pH7.4

 

Description :

Interleukin 13 (IL13) is also known as ALRH, BHR1and P600, is a single-chain glycosylated polypeptide, and is a cytokine critical in regulating inflammatory and immune responses. IL13 is secreted by many cell types, but especially by T helper type 2 (Th2) cells. IL-13 induces its effects through a multi-subunit receptor that includes the alpha chain of the IL-4 receptor (IL-4Rα) and at least one of two known IL-13-specific binding chains. The functions of IL-13 overlap considerably with those of IL-4, especially with regard to changes induced on hematopoietic cells, but these effects are probably less important given the more potent role of IL-4. IL-13 induces matrix metalloproteinases (MMPs) as part of a mechanism that protects against excessive allergic inflammation that predisposes to asphyxiation. IL-13 induces many features of allergic lung disease, including airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion, which all contribute to airway obstruction.

 

References :

(1) Wynn TA., 2003, Annu. Rev. Immunol., 21: 425-456.
(2) Wills-Karp M, et al., 1998, Science, 282 (5397): 2258-2261.
(3) Zurawski G., et al., 1994, Immunol. Today., 15 (1): 19-26.